Insulin-pump software maps blood-glucose events

January 15, 2011

Medtronic Inc. in Minneapolis, Minn., recently received FDA approval for its new CareLink Pro 3.0 Therapy Management software.

Monitoring diabetes patients' care is getting a lot more technological, but in a user-friendly way.

Medtronic Inc. in Minneapolis, Minn., recently received FDA approval for its new CareLink Pro 3.0 Therapy Management. By analyzing data from a patient's insulin pump, continuous glucose-monitoring (CGM) device, and blood-glucose meter, and presenting the results on one dashboard, the software gives providers a snapshot of key insulin-delivery and glucose information, pinpointing when patients experience low and high glucose patterns. By prioritizing those patterns, the software indicates times of day that are the biggest challenges for patients.

Medtronic's recent STAR 3 Trial showed that 485 patients in all age groups (adults, teens, and children), using the Medtronic integrated system, achieved a statistically significant reduction in HbA1C without an increase in hypoglycemia.